Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...2627282930313233343536...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal:  Diabetes Drug AIDS Weight Reduction in Adults. (Pubmed Central) -  Apr 21, 2021   
    According to this study: In adults who were obese or overweight, once-weekly subcutaneous semaglutide administration in addition to lifestyle interventions resulted in sustained, clinically relevant weight loss.
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Trial completion:  A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) -  Apr 19, 2021   
    P1,  N=85, Completed, 
    According to this study: In adults who were obese or overweight, once-weekly subcutaneous semaglutide administration in addition to lifestyle interventions resulted in sustained, clinically relevant weight loss. Active, not recruiting --> Completed
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
    Journal, HEOR:  Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. (Pubmed Central) -  Apr 15, 2021   
    Not yet recruiting --> Enrolling by invitation Once-weekly semaglutide 0.5 mg and 1 mg were considered dominant (more effective and less costly) versus sitagliptin 100 mg and dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resources in the Spanish setting.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Enrollment open:  ESSENCE: Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) -  Apr 12, 2021   
    P3,  N=1200, Recruiting, 
    Once-weekly semaglutide 0.5 mg and 1 mg were considered dominant (more effective and less costly) versus sitagliptin 100 mg and dulaglutide 1.5 mg for the treatment of patients with type 2 diabetes with inadequate glycemic control on oral anti-hyperglycemic medications and are likely to be a good use of healthcare resources in the Spanish setting. Not yet recruiting --> Recruiting
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: A cost of control analysis. (Pubmed Central) -  Apr 7, 2021   
    All other interventions were associated with higher cost of control values for both targets. Oral semaglutide 14 mg is likely to be cost-effective versus dulaglutide, exenatide (once weekly and twice daily), liraglutide, and lixisenatide in terms of bringing people with type 2 diabetes to glycemic control targets of HbA1c ≤6.5% and HbA1c <7.0% in the US.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal:  Once-Weekly Semaglutide in Adults with Overweight or Obesity. (Pubmed Central) -  Mar 31, 2021   
    P3
    In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk
    Clinical, Review, Journal, Head-to-Head:  GLP-1 receptor agonists: an updated review of head-to-head clinical studies. (Pubmed Central) -  Mar 27, 2021   
    Through a review of phase III clinical trials studying dulaglutide, exenatide twice daily, exenatide once weekly, liraglutide, lixisenatide, semaglutide, and oral semaglutide, 14 head-to-head trials were identified that evaluated the safety and efficacy of GLP-1 RA active comparators...The GLP-1 RA head-to-head clinical studies have demonstrated that all GLP-1 RA agents are effective therapeutic options at reducing A1C. However, differences exist in terms of magnitude of effect on A1C and weight as well as frequency of adverse effects.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca, semaglutide SC once-daily (NN9536) / Novo Nordisk
    [VIRTUAL] Efficacy of Semaglutide by Background Sodium – Glucose Co-Transporter-2 Inhibitor: a Post Hoc Analysis of SUSTAIN 9 (Channel 4) -  Mar 21, 2021 - Abstract #DDG2021DDG_469;    
    SUSTAIN 9 investigated semaglutide 1.0 mg vs placebo as add-on to a stable dose of sodium-glucose co transporter-2 inhibitor (SGLT-2i) therapy, with or without metformin or a sulfonylurea...In this post hoc analysis, SUSTAIN 9 data were analyzed by background SGLT-2i (empagliflozin, canagliflozin, dapagliflozin or other [ipragliflozin, luseogliflozin and tofogliflozin; drugs available only in Japan])...In conclusion, in subjects with T2D already receiving an SGLT-2i, semaglutide generally resulted in superior HbA1c and body weight reductions vs placebo, regardless of background SGLT-2i therapy. Joachim Kienhöfer is just presenting on behalf of the author group (Sponsored by Novo Nordisk A / S).
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    [VIRTUAL] THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES: RESULTS FROM THE LEADER AND SUSTAIN 6 TRIALS (Virtual Hall 2) -  Mar 19, 2021 - Abstract #ERAEDTA2021ERA_EDTA_606;    
    P3
    In patients with type 2 diabetes, improvements in two or more risk markers confer reduced risk of cardiovascular disease and nephropathy as compared with none or one improved risk marker, most notably for nephropathy. Our findings stress the importance of multifactorial intervention and underscore the benefit of pleiotropic antidiabetic treatments.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Enrollment change:  Effects of Semaglutide in HIV-Associated Lipohypertrophy (clinicaltrials.gov) -  Mar 18, 2021   
    P2,  N=104, Recruiting, 
    Active, not recruiting --> Completed N=208 --> 104
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Enrollment open:  COMBAT_T2_NASH: Combined Active Treatment in Type 2 Diabetes With NASH (clinicaltrials.gov) -  Mar 9, 2021   
    P4,  N=192, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    [VIRTUAL] SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS REGARDLESS OF METFORMIN USE: A POST HOC EXPLORATORY SUBGROUP ANALYSIS OF SUSTAIN 6 AND PIONEER 6 (eAbstract site) -  Feb 17, 2021 - Abstract #ACC2021ACC_8080;    
    Background: Post hoc analyses of liraglutide, dulaglutide and empagliflozin cardiovascular outcomes trials (CVOTs) showed reductions in major adverse cardiovascular events (MACE) regardless of baseline metformin (MET) use... No difference in outcomes could be detected between MET subgroups, indicating that semaglutide provides CV and metabolic benefits in subjects regardless of MET use.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    [VIRTUAL] TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 1 TRIAL (eAbstract site) -  Feb 17, 2021 - Abstract #ACC2021ACC_2519;    
    P3
    No difference in outcomes could be detected between MET subgroups, indicating that semaglutide provides CV and metabolic benefits in subjects regardless of MET use. Semaglutide 2.4 mg OW treatment for 68 wks led to superior BW reductions and greater improvements in CM risk factors, vs PBO, suggesting favorable CM effects of semaglutide beyond BW loss.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Retrospective data, Journal:  Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis. (Pubmed Central) -  Feb 17, 2021   
    Semaglutide 2.4 mg OW treatment for 68 wks led to superior BW reductions and greater improvements in CM risk factors, vs PBO, suggesting favorable CM effects of semaglutide beyond BW loss. This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial primary completion date:  A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage (clinicaltrials.gov) -  Feb 15, 2021   
    P2,  N=65, Active, not recruiting, 
    This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy. Trial primary completion date: Jan 2021 --> Apr 2021